Hereditary transthyretin amyloidosis

What is Hereditary transthyretin amyloidosis?

Hereditary transthyretin amyloidosis (hATTR), also known as ATTRv amyloidosis, is a rare inherited disorder where abnormal protein deposits accumulate in tissues throughout the body, particularly affecting the nerves and heart. The condition is caused by mutations in the TTR gene, which produces transthyretin protein that becomes misfolded and forms toxic amyloid deposits. This progressive disease primarily affects adults and manifests with nerve damage (neuropathy), heart problems (cardiomyopathy), and other organ dysfunction. With approximately 50,000 cases worldwide, hATTR represents a significant challenge for patients and families, though recent therapeutic advances offer renewed hope.

Key statistics

Symptoms

Primary symptoms: Progressive numbness and tingling in hands and feet, heart rhythm abnormalities, carpal tunnel syndrome, gastrointestinal problems, weight loss, fatigue, muscle weakness.

The symptoms of hATTR typically develop gradually and vary depending on which organs are most affected. Neurological manifestations often begin with a length-dependent neuropathy, starting in the feet and hands with burning pain, numbness, and loss of temperature sensation. Patients frequently experience severe neuropathic pain that worsens at night. Carpal tunnel syndrome may be an early sign, sometimes appearing years before other symptoms.

Cardiovascular features include heart failure, arrhythmias, and thickening of the heart muscle (cardiomyopathy). Some patients develop conduction abnormalities requiring pacemaker implantation.

Submit Your Paper

Autonomic dysfunction affects multiple body systems, causing gastrointestinal problems like severe diarrhea alternating with constipation, gastroparesis, early satiety, and unintentional weight loss. Sexual dysfunction, orthostatic hypotension, and altered sweating patterns are also common.

Other manifestations may include eye problems (vitreous opacities), kidney disease, and in some cases, central nervous system involvement leading to stroke-like episodes or dementia.

Causes and risk factors

hATTR is caused by mutations in the TTR gene located on chromosome 18. This gene provides instructions for making transthyretin protein, normally produced by the liver and involved in transporting thyroid hormone and vitamin A. Over 140 different TTR mutations have been identified, with some being more common in specific geographic regions.

The condition follows an autosomal dominant inheritance pattern, meaning only one copy of the mutated gene is needed to cause disease. However, penetrance is incomplete and age-dependent, so not everyone who inherits the mutation will develop symptoms.

Risk factors include family history of the condition, specific ethnic backgrounds (such as Portuguese, Swedish, or Japanese ancestry for certain mutations), and advancing age. Environmental factors do not appear to significantly influence disease development, though they may affect symptom progression.

Prevention

As hATTR is an inherited genetic condition, primary prevention is not possible. However, genetic counseling and testing are crucial for at-risk family members. Pre-symptomatic genetic testing can identify mutation carriers before symptoms develop, allowing for early monitoring and potential intervention.

Reproductive options for affected individuals include preimplantation genetic diagnosis (PGD) during in vitro fertilization to select embryos without the mutation. Genetic counseling is essential to help families understand inheritance risks, testing options, and reproductive choices.

Early detection through family screening and genetic testing enables prompt treatment initiation, which can significantly slow disease progression and improve outcomes.

Complications

Without treatment, hATTR progressively worsens, leading to severe disability and reduced life expectancy. Advanced neuropathy can result in complete loss of sensation in hands and feet, severe chronic pain, and muscle weakness requiring mobility aids or wheelchair dependence.

Cardiac complications include heart failure, potentially fatal arrhythmias, and sudden cardiac death. The restrictive cardiomyopathy characteristic of hATTR can severely limit physical activity and quality of life.

Severe autonomic dysfunction may lead to malnutrition, dangerous blood pressure fluctuations, and gastrointestinal complications requiring nutritional support. Advanced kidney disease may necessitate dialysis or transplantation.

The combination of progressive disability, chronic pain, and multiple organ dysfunction significantly impacts mental health, with depression and anxiety being common complications.

Diagnosis

Diagnosing hATTR requires a combination of clinical assessment, specialized testing, and genetic confirmation. The diagnostic journey often involves multiple specialists due to the condition’s diverse manifestations.

Genetic testing for TTR mutations provides definitive diagnosis and should be performed in patients with suggestive symptoms or family history.

Tissue biopsy with Congo red staining can demonstrate amyloid deposits, while mass spectrometry typing confirms TTR amyloid. Common biopsy sites include abdominal fat pad, nerve, or heart tissue.

Cardiac imaging using echocardiography shows characteristic wall thickening, while cardiac MRI with gadolinium enhancement and nuclear medicine scans (99mTc-PYP or DPD scintigraphy) can detect cardiac amyloid deposits.

Neurological testing includes nerve conduction studies and electromyography to assess peripheral nerve damage. Autonomic function testing may reveal dysfunction in multiple systems.

Laboratory tests may show elevated cardiac biomarkers (NT-proBNP, troponin) and require exclusion of other causes of amyloidosis, including serum and urine protein electrophoresis.

Treatment

Treatment for hATTR has been revolutionized by the approval of several disease-modifying therapies that target different aspects of the disease process.

TTR stabilizers prevent protein misfolding and include tafamidis and acoramidis. These medications have demonstrated significant benefits in slowing neuropathy progression and reducing cardiovascular complications.

RNA interference therapies reduce TTR protein production by the liver. Patisiran and vutrisiran are administered by intravenous infusion or subcutaneous injection, respectively, and have shown remarkable efficacy in halting or even reversing neuropathy progression.

Antisense oligonucleotides like inotersen also reduce TTR production but require careful monitoring due to potential side effects including thrombocytopenia and kidney problems.

Supportive care remains crucial and includes pain management with anticonvulsants or antidepressants for neuropathic pain, cardiac medications for heart failure and arrhythmias, and nutritional support for gastrointestinal complications.

Organ transplantation may be considered in advanced cases, with liver transplantation historically used to remove the source of mutant TTR protein, though newer medications have largely replaced this approach.

Prognosis

The prognosis for hATTR has improved dramatically with the introduction of effective therapies. Historically, untreated disease led to death within 10-20 years of symptom onset, with cardiac and neurological complications being the primary causes of mortality.

With early diagnosis and appropriate treatment, disease progression can be significantly slowed or halted. Patients who begin treatment before advanced organ damage has occurred generally have better outcomes. Cardiac involvement typically carries a more guarded prognosis, though newer therapies show promise in improving cardiac outcomes.

The specific TTR mutation influences prognosis, with some variants causing more aggressive disease. Regular monitoring and treatment adjustments can optimize outcomes, and many patients can maintain reasonable quality of life with current therapies.

Quality of life

Managing hATTR requires a comprehensive approach to maintain quality of life. Regular exercise within individual limitations helps preserve muscle strength and cardiovascular health, though activities may need modification as the disease progresses.

Dietary modifications can help manage gastrointestinal symptoms, including small frequent meals, adequate hydration, and nutritional supplementation when needed. A dietitian familiar with amyloidosis can provide valuable guidance.

Pain management is crucial for quality of life, often requiring multimodal approaches including medications, physical therapy, and sometimes psychological support. Occupational therapy can help with adaptive equipment and home modifications.

Mental health support is essential, as chronic illness significantly impacts emotional well-being. Support groups, counseling, and connection with other patients can provide valuable coping strategies and emotional support.

Work accommodations may be necessary as symptoms progress, and disability planning should be considered early in the disease course.

Pregnancy and fertility

hATTR typically affects individuals beyond reproductive age, but pregnancy considerations are important for younger patients and family planning. The condition itself does not directly affect fertility, though general health impacts may influence reproductive capacity.

Pregnancy management requires careful consideration of medication safety, as data on newer hATTR therapies during pregnancy are limited. Some treatments may need to be discontinued or modified during pregnancy and breastfeeding.

Genetic counseling is crucial before pregnancy to discuss inheritance risks and reproductive options. Each pregnancy carries a 50% risk of transmitting the mutation to the child, making preimplantation genetic diagnosis an important consideration for some families.

Children

hATTR rarely manifests in childhood, with most symptoms appearing in adulthood. However, children may carry the genetic mutation and benefit from genetic counseling and family education about the condition.

For families affected by hATTR, age-appropriate education about the genetic nature of the condition helps children understand family medical history and future health monitoring needs.

Genetic testing in minors is generally not recommended unless there are clinical indications, as the psychological impact and limited immediate medical benefit must be carefully weighed.

When to see a doctor

Immediate medical attention is needed for symptoms suggesting heart failure (shortness of breath, leg swelling, chest pain), dangerous heart rhythms (palpitations, dizziness, fainting), or severe gastrointestinal symptoms causing dehydration or malnutrition.

Routine medical evaluation should be sought for progressive numbness or tingling in hands and feet, unexplained weight loss, recurrent carpal tunnel syndrome, or family history of amyloidosis or unexplained heart failure.

Regular follow-up with specialists familiar with hATTR is essential for monitoring disease progression and treatment response, typically every 3-6 months depending on disease stage and treatment.

Regional context

Specific prevalence data for hereditary transthyretin amyloidosis in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean are limited. However, certain TTR mutations show geographic clustering, and founder effects may result in higher prevalence in isolated populations.

We invite healthcare professionals and researchers from these regions to contribute data and insights about hATTR prevalence, common mutations, and clinical presentations to the Global Medical Journal to enhance regional medical knowledge and patient care.

Research and clinical trials

Research in hATTR continues to advance rapidly, with investigations into gene editing technologies, novel therapeutic targets, and combination therapies. CRISPR-based approaches show promise for permanent reduction of TTR production.

Current clinical trials are exploring new medications, improved delivery systems, and treatments for advanced disease manifestations. Studies are also investigating optimal timing of treatment initiation and combination therapy approaches.

The ClinicalTrials.gov database lists numerous ongoing studies for hATTR, providing opportunities for patients to access experimental treatments and contribute to advancing medical knowledge.

Biomarker research aims to improve early detection and monitoring of treatment response, while natural history studies help understand disease progression patterns.

Frequently asked questions

Will I definitely develop hATTR if I have the genetic mutation?

Not necessarily. While hATTR follows autosomal dominant inheritance, penetrance is incomplete and age-dependent. Some people with mutations never develop symptoms, while others may have later onset or milder disease.

How quickly does hATTR progress?

Disease progression varies significantly depending on the specific mutation, age of onset, and organs affected. Some patients experience rapid progression over months, while others have slowly progressive disease over many years. Early treatment can significantly slow progression.

Can hATTR be cured?

Currently, there is no cure for hATTR, but highly effective treatments can halt or slow disease progression. Early intervention with approved therapies can prevent irreversible organ damage and maintain quality of life.

Is hATTR the same as other types of amyloidosis?

No. hATTR is specifically caused by mutations in the TTR gene and is inherited. Other forms like AL amyloidosis are acquired conditions with different causes, symptoms, and treatments.

Should my family members be tested for hATTR?

Family members should consider genetic counseling to discuss testing options. First-degree relatives have a 50% chance of carrying the mutation. Testing decisions should consider psychological readiness, family planning, and availability of monitoring and treatment.

Support and resources

Patient Organizations:
– Amyloidosis Foundation: amyloidosis.org
– Amyloidosis Research Consortium: arci.org

International Resources:
– Orphanet: orpha.net
– National Organization for Rare Disorders (NORD): rarediseases.org
– EURORDIS: eurordis.org
– Global Genes: globalgenes.org

Clinical Trial Information:
– ClinicalTrials.gov: clinicaltrials.gov

Related conditions

– Wild-type transthyretin amyloidosis
– Light chain amyloidosis
– Familial amyloid polyneuropathy
– Hypertrophic cardiomyopathy
– Hereditary neuropathy

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.